Last reviewed · How we verify
Migergot (ERGOTAMINE)
Migergot (Ergotamine) is a small molecule ergot derivative that targets the 5-hydroxytryptamine receptor 1A. It was originally developed and is currently owned by various companies. FDA approved in 1948, it is used to treat cluster headache prevention, cluster headache syndrome, migraine, and vascular headache. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its low bioavailability and short half-life.
At a glance
| Generic name | ERGOTAMINE |
|---|---|
| Drug class | Central Nervous System Stimulant [EPC] |
| Target | 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1948 |
Approved indications
- Cluster Headache Prevention
- Cluster headache syndrome
- Migraine
- Vascular headache
Boxed warnings
- WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of ergotamine tartrate and caffeine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See also CONTRAINDICATIONS and WARNINGS section)
Common side effects
- Hypertension
- Nausea
- Vomiting
- Tachycardia
- Bradycardia
- Paresthesias
- Numbness
- Weakness
- Vertigo
- Localized edema
- Itching
Drug interactions
- delavirdine
- efavirenz
- erythromycin
- fenfluramine
- fosamprenavir
- glyceryl trinitrate
- indinavir
- itraconazole
- ketoconazole
- lopinavir
- naratriptan
- nelfinavir
Key clinical trials
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- Dopamine Action on Metabolism in Relation to Genotype (PHASE2)
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Bromocriptine for Patients With Schizophrenia and Prediabetes (PHASE4)
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (PHASE1,PHASE2)
- Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa (EARLY_PHASE1)
- Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |